Detalhe da pesquisa
1.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 403(10434): 1341-1350, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521086
2.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126311
3.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med
; 381(1): 13-24, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31150574
4.
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
J Urol
; 206(4): 914-923, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34039013
5.
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 20(11): 1518-1530, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578173
7.
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Eur J Cancer
; 193: 113290, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708629
8.
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol
; 41(18): 3339-3351, 2023 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952634
9.
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
J Clin Oncol
; 39(20): 2294-2303, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914595